RAYOPTA Trademark

Trademark Overview

On Monday, July 9, 2018, a trademark application was filed for RAYOPTA with the United States Patent and Trademark Office. The USPTO has given the RAYOPTA trademark a serial number of 88029974. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, March 14, 2022. This trademark is owned by Allergan Development Ventures I LP. The RAYOPTA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of macular degeneration
rayopta

General Information

Serial Number88029974
Word MarkRAYOPTA
Filing DateMonday, July 9, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, March 14, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 11, 2018

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of macular degeneration

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, July 13, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAllergan Development Ventures I LP
Party Type20 - Owner at Publication
Legal Entity Type13 - Limited Partnership
AddressHamilton HM12
BM
Party NameAllergan Development Ventures I LP
Party Type10 - Original Applicant
Legal Entity Type13 - Limited Partnership
AddressHamilton HM12
BM

Trademark Events

Event DateEvent Description
Monday, March 14, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, March 14, 2022ABANDONMENT - NO USE STATEMENT FILED
Thursday, August 12, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 11, 2021EXTENSION 5 GRANTED
Thursday, August 5, 2021EXTENSION 5 FILED
Wednesday, August 11, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, August 5, 2021TEAS EXTENSION RECEIVED
Tuesday, August 3, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, August 3, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, August 3, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, July 22, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, February 4, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, February 2, 2021EXTENSION 4 GRANTED
Tuesday, February 2, 2021EXTENSION 4 FILED
Tuesday, February 2, 2021TEAS EXTENSION RECEIVED
Friday, July 3, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 1, 2020EXTENSION 3 GRANTED
Wednesday, July 1, 2020EXTENSION 3 FILED
Wednesday, July 1, 2020TEAS EXTENSION RECEIVED
Thursday, February 6, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, February 4, 2020EXTENSION 2 GRANTED
Tuesday, February 4, 2020EXTENSION 2 FILED
Tuesday, February 4, 2020TEAS EXTENSION RECEIVED
Tuesday, July 9, 2019TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, July 11, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 9, 2019EXTENSION 1 GRANTED
Tuesday, July 9, 2019EXTENSION 1 FILED
Tuesday, July 9, 2019TEAS EXTENSION RECEIVED
Tuesday, February 5, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 11, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 11, 2018PUBLISHED FOR OPPOSITION
Wednesday, November 21, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, October 29, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, October 26, 2018ASSIGNED TO EXAMINER
Friday, July 13, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, July 12, 2018NEW APPLICATION ENTERED IN TRAM

Related Keywords

rayopta degeneration macular treatment preparations pharmaceutical